TABLE 3.
Cox proportional hazards model of local recurrence‐free survival for total study population.
| Characteristics | Univariable | Multivariable | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p | HR | 95% CI | p | |
| Menopausal status | ||||||
| Premenopausal | 1 (ref) | |||||
| Postmenopausal | 0.790 | 0.528–1.181 | 0.2504 | |||
| Type of surgery | ||||||
| BCS | 1 (ref) | < 0.0001 | ||||
| TM | 3.410 | 1.633–7.120 | 0.0011 | |||
| NSM | 4.515 | 2.902–7.026 | < 0.0001 | |||
| Tumor multiplicity | ||||||
| Single | 1 (ref) | 1 (ref) | ||||
| Multiple (≥ 2) | 1.977 | 1.211–3.228 | 0.0064 | 1.833 | 1.117–3.008 | 0.0166 |
| Tumor size a | 1.276 | 1.158–1.406 | < 0.0001 | |||
| Pathological T stage | ||||||
| T1mi | 1 (ref) | 0.0029 | ||||
| Tis | 0.628 | 0.344–1.148 | 0.1306 | |||
| T1a | 0.276 | 0.102–0.747 | 0.0113 | |||
| T1b | 0.536 | 0.274–1.05 | 0.0693 | |||
| T1c | 0.342 | 0.19–0.614 | 0.0003 | |||
| Ki‐67 (n = 2370) | ||||||
| ≤ 14% | 1 (ref) | 1 (ref) | ||||
| > 14% | 2.101 | 1.368–3.226 | 0.0007 | 1.749 | 1.072–2.855 | 0.0253 |
| Subtype (n = 2384) | ||||||
| ER/PR+ HER2− | 1 (ref) | < 0.0001 | 1 (ref) | 0.0338 | ||
| ER/PR+ HER2+ | 2.538 | 1.427–4.513 | < 0.0001 | 1.977 | 1.062–3.681 | 0.0316 |
| ER/PR− HER2+ | 3.088 | 1.873–5.091 | < 0.0001 | 0.843 | 0.392–1.816 | 0.6632 |
| ER/PR− HER2− | 1.588 | 0.827–3.046 | 0.1644 | 0.600 | 0.247–1.455 | 0.2582 |
| Chemotherapy | ||||||
| No | 1 (ref) | |||||
| Yes | 0.737 | 0.455–1.193 | 0.2138 | |||
| Endocrine therapy | ||||||
| No | 1 (ref) | 1 (ref) | ||||
| Yes | 0.329 | 0.222–0.487 | < 0.0001 | 0.374 | 0.198–0.708 | 0.0025 |
| Anti‐HER2 therapy | ||||||
| No | 1 (ref) | |||||
| Yes | 0.909 | 0.422–1.96 | 0.8083 | |||
| Radiation therapy | ||||||
| No | 1 (ref) | 1 (ref) | ||||
| Yes | 0.190 | 0.128–0.282 | < 0.0001 | 0.225 | 0.147–0.343 | < 0.0001 |
Note: The p‐values that are statistically significant have been highlighted in bold.
Abbreviations: BCS, breast‐conserving surgery; CI, confidence interval; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; NSM, nipple‐sparing mastectomy; PR, progesterone receptor; ref, reference; TM, total mastectomy.
a
Tumor size was measured as the size of the invasive focus in T1a–c tumors, and as the size of the largest lesion, either invasive focus or in situ component, in Tis and T1mi tumors.